Comments
Commented by Fabian Lorenz on October 16th, 2025 | 07:05 CEST
Takeover fever and AI Opportunities: BioNTech, Novo Nordisk, PanGenomic Health
The pharmaceutical and biotech sector is buzzing with takeover activity. Following the announcement of a billion-dollar acquisition in the US, Novo Nordisk has announced its next deal, eyeing a potential best-in-class therapeutic for several rare diseases. Meanwhile, PanGenomic Health is positioning itself in the billion-dollar market for alternative medicine and dietary supplements, leveraging AI to provide added value to customers and capture market share. If successful, the stock could be significantly undervalued. BioNTech's acquisition of CureVac has now been completed, ending CureVac's period of suffering. In the process, BioNTech secures patents and elegantly resolves ongoing legal disputes.
Read
Commented by Nico Popp on October 16th, 2025 | 07:00 CEST
Who definitely deserves credit in the fight against cancer: NetraMark, Moderna, BioNTech
Two biotech pioneers, Moderna and BioNTech, are back in the spotlight after their COVID-19 vaccine success - this time in a race to develop innovative cancer therapies. Both companies rely on mRNA technology to develop personalized cancer vaccines. Speed is crucial here: whoever brings effective treatments to market first could secure billions in market share. At the same time, AI startup NetraMark is entering the stage with novel data analysis that could significantly accelerate research and shape medical progress. We shed light on what is currently driving both the research community and investors.
Read
Commented by Fabian Lorenz on October 15th, 2025 | 08:35 CEST
BUYING OPPORTUNITY or Sell? Plug Power, Gerresheimer, AI insider tip NetraMark!
The stock markets are using the tariff dispute between the US and China as a reason for a correction. As a result, AI insider tip NetraMark has lost around 30% of its value in recent weeks. However, there is positive company news, and pressure from the US government on the biotech and pharmaceutical industry should generate additional interest in NetraMark's technology. So, is the correction a buying opportunity? And what about Plug Power? After the spectacular rise in the share price, the first analyst is already sounding a warning. Losses, and thus financing requirements, are likely to remain high. Gerresheimer's price targets are currently tumbling. Unfortunately, however, analysts are only just catching up with the stock's decline. Buy now or even sell?
Read
Commented by André Will-Laudien on October 15th, 2025 | 08:30 CEST
Correction and high volatility- Triple AAA is the order of the day: Amazon, Aspermont, and Alibaba keep their promises!
A lot is happening right now — up and down, left and right! Stock markets have become increasingly volatile, reacting to the latest political statements, especially those from US President Donald Trump. While the crypto world is experiencing a sharp correction, investors are once again turning to precious metals and critical raw materials. Aspermont is an expert in raw materials. The Company has been building its network for several decades – now the harvest phase seems to be starting. Amazon and Alibaba have already launched their Black Friday sales this year, but the big shopping event kicks off with Thanksgiving. We take a closer look at profitable business models and strong stocks that are well-positioned to weather the next storm!
Read
Commented by Carsten Mainitz on October 15th, 2025 | 08:25 CEST
If you are looking for outperformance, you will find it here: Nakiki, Strategy, Palantir!
Cryptocurrencies are currently still digesting the latest flash crash, which briefly sent the BTC price from its all-time high of over USD 126,000 down to USD 107,000. It has now stabilized around USD 110,000. For investors, corrections in an intact upward trend are always excellent opportunities to build or expand positions. US investment bank JPMorgan is forecasting prices of USD 165,000 for Bitcoin this year. Sounds like a very high return? Yes, but it gets even better: Strategy has already shown the way. So-called BTC treasury strategies are outperforming cryptocurrencies. We take a closer look at the strategy and the exciting, promising newcomer, Nakiki SE.
Read
Commented by Armin Schulz on October 15th, 2025 | 07:15 CEST
How your portfolio can benefit from the green energy boom with Nordex, RE Royalties, and JinkoSolar
Winners despite turbulent times: As the global energy transition gains momentum, a future market worth billions is emerging. Ever-larger wind turbines, more cost-effective solar modules, and an explosive growth in demand for green electricity are driving the revolution. Innovative companies that produce, finance, or supply clean energy are at the heart of this boom. Three promising players have already positioned themselves and could benefit directly: Nordex, RE Royalties, and JinkoSolar.
Read
Commented by Nico Popp on October 15th, 2025 | 07:10 CEST
Hydrogen boom ahead: BMW, Toyota, Pure Hydrogen
Has the hydrogen hype cooled off? Not at all! Large companies are still investing heavily in this energy carrier. Industrial companies, such as those in the chemical sector, as well as automakers like BMW and Toyota, are all offering innovations related to hydrogen. But hydrogen is not just a topic for large corporations. Smaller mid-sized companies also need solutions for renewable energy for their factories or vehicle fleets. This is where the Australian company Pure Hydrogen comes into play – the hydrogen specialists' focus is on holistic solutions.
Read
Commented by André Will-Laudien on October 15th, 2025 | 07:05 CEST
Supply chains on the NASDAQ! Critical metals sold out? What is next for Almonty - Caution advised with Rheinmetall, Deutz, and RENK
Snip-Snap! In and out of the markets! At the moment, all stock market wisdom applies, because there is nothing more unpredictable for investors than the current US president. And who would have thought that the critical metal supply chains would suddenly become a major driving force behind the NASDAQ rally? Just as Xi Jinping threw rare metals into the ring as a bargaining chip, Donald Trump blew a fuse. Punitive tariffs of up to 100% were suddenly on the table, and the markets went into a tailspin. Yet just one trading day later, everything is put into perspective, and the markets have to find their new valuation point – no easy task. Yesterday, nervousness returned, as reflected in a sharp rise in the volatility index. What should investors be keeping a close eye on now?
Read
Commented by Armin Schulz on October 15th, 2025 | 07:00 CEST
Volkswagen in a tight spot: Why European Lithium and Standard Lithium are now the more valuable players
The global electric vehicle revolution is facing its biggest test yet. China's looming export restrictions on critical battery raw materials threaten to destabilize Western manufacturers' supply chains from 2025 and increase production costs. But it is precisely these geopolitical tensions that are catapulting independent lithium producers into the spotlight. While established giants are fighting for their security of supply, agile players are benefiting from this power vacuum. The strategic maneuvers of Volkswagen, European Lithium, and Standard Lithium reveal who the real winners of this upheaval will be.
Read
Commented by Fabian Lorenz on October 14th, 2025 | 07:30 CEST
Alternative to BioNTech, Evotec, and Co.: BioNxt Solutions impresses at investor conference and sparks takeover speculation
While the shares of BioNTech and Evotec are treading water, BioNxt Solutions is on an upward trajectory. The Company is currently shaking up Big Pharma. The announcement to replace the weight-loss injection Ozempic with an oral dissolvable film has sparked takeover speculation. BioNxt also aims to make waves in multiple sclerosis, another multi-billion-dollar market, by significantly simplifying the administration of a blockbuster drug for patients. At last week's IIF investor conference, the management board delivered a convincing presentation. Partnerships and licensing opportunities were outlined - assuming no acquisition occurs beforehand. This could prove highly rewarding for both a pharmaceutical company and shareholders.
Read